ESTRO 2024 - Abstract Book

S664

Clinical - Breast

ESTRO 2024

Intermediate (11-40%)

66

81.5

High (41-90%)

12

14.8

Unknown

0

0

3

3.7

Chemotherapy

Yes

2

2.5

No

79

97.5

Hormone therapy

Yes

76

93.8

No

5

6.2

Adherence to hormone therapy

Yes

No

61

75.3

20

24.7

Acute adverse effects

N

%

Seroma

14

17.3

Edema

3

3.7

Hematoma

3

3.7

Chronic adverse effects

N

%

Fat necrosis

4

4.9

Fibrosis

1 3

1.2 3.7

Localizad pain

Figure 1: Association between breast carcinoma subtype and stromal percentage of TILs